Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis.
Qiu WeiHua LinRong-Guo WeiNian ChenFan HeDong-Hua ZouJin-Ru WeiPublished in: Infectious diseases of poverty (2021)
Our study shows that tocilizumab treatment is associated with a lower risk of mortality and mechanical ventilation requirement among COVID-19 patients. Tocilizumab may have substantial effectiveness in reducing mortality among COVID-19 patients, especially among critical cases. This systematic review provides an up-to-date evidence of potential therapeutic role of tocilizumab in COVID-19 management.
Keyphrases
- sars cov
- rheumatoid arthritis
- systematic review
- mechanical ventilation
- juvenile idiopathic arthritis
- rheumatoid arthritis patients
- intensive care unit
- coronavirus disease
- cardiovascular events
- randomized controlled trial
- acute respiratory distress syndrome
- cardiovascular disease
- type diabetes
- systemic lupus erythematosus
- smoking cessation